on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Reports Record Year in 2024
Berlin, March 27, 2025 - Eckert & Ziegler SE announced a record financial performance for 2024, with sales reaching €295.8 million, a 20% increase from the previous year. The growth was driven by a remarkable demand in the Medical segment, where sales surged by 29% to €148.4 million, primarily due to radiopharmaceuticals. The Isotope Products segment also saw a 13% increase with sales hitting €147.5 million, attributed to pricing and volume adjustments.
EBIT before special items rose by 40% to €65.9 million, while net income grew by 27% to €33.3 million, translating to earnings per share of €1.60. For 2025, the company anticipates sales of around €320 million and an adjusted EBIT of approximately €78 million.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news